Zacks Investment Research on MSN
Masimo stock declines despite solid preliminary Q4 revenues
Masimo Corporation MASI announced preliminary revenues for the fourth quarter and full year 2025 on Monday. Despite the ...
Masimo (NASDAQ:MASI) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table summarizes their recent ratings, shedding ...
Masimo Corporation (Nasdaq: MASI) today announced select preliminary financial results for the fourth quarter and full-year ...
Zacks.com on MSN
Here's Why You Should Retain Masimo Stock in Your Portfolio Now
MASI's strong Q3 2025 results, FDA clearance and partnerships fuel growth hopes, but SET dependence and reimbursement risks ...
The Irvine-based medical device maker expects Q4 revenue to increase 12% to $411 million and full year revenue to grow 9% to $1.5 billion.
Medical device company Masimo has accused Apple of patent infringement, filing a complaint against the company with the U.S. International Trade Commission yesterday. Bloomberg, which first spotted ...
Mixed bag of news for Apple as Masimo tumbles in quality despite patent win, on-device AI threatens data centers, and the Tim ...
Masimo (Nasdaq: MASI) is a global technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, ...
A federal jury Friday ruled that Masimo's smartwatches infringed on Apple Watch patents, but awarded Apple just $250 in damages, which is the statuary minimum amount Apple could seek while it pursues ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback